Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LY3541105
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Expanded Collaboration
KeyBioscience Announces Extension of Strategic Collaboration with Lilly
Details : Lilly will receive worldwide rights to develop and commercialize Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of potential treatments for obesity and related disorders.
Brand Name : LY3541105
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : LY3541105
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Expanded Collaboration
LOOKING FOR A SUPPLIER?